The global Drug Particle Engineering Service market size is predicted to grow from US$ 1199 million in 2025 to US$ 1558 million in 2031; it is expected to grow at a CAGR of 4.5% from 2025 to 2031.
Drug particle engineering service is a comprehensive service that provides particle design, preparation, characterization, and optimization services for drug development and production. This service aims to improve the physical properties of drugs, increase their solubility and bioavailability, and thereby enhance their efficacy and safety through advanced particle engineering techniques. Drug Particle Engineering Service covers the entire process from the design and preparation of drug particles to their characterization and optimization, including the regulation of particle size, shape, and surface properties. Through this service, customers can obtain drug products with specific particle characteristics to meet their needs for new drug development and production. Additionally, this service provides professional technical support and solutions to help customers solve particle-related issues encountered during drug development and production.
United States market for Drug Particle Engineering Service is estimated to increase from US$ million in 2024 to US$ million by 2031, at a CAGR of % from 2025 through 2031.
China market for Drug Particle Engineering Service is estimated to increase from US$ million in 2024 to US$ million by 2031, at a CAGR of % from 2025 through 2031.
Europe market for Drug Particle Engineering Service is estimated to increase from US$ million in 2024 to US$ million by 2031, at a CAGR of % from 2025 through 2031.
Global key Drug Particle Engineering Service players cover Lonza, CritiTech, EUROAPI, Schedio, Solid State Pharma, etc. In terms of revenue, the global two largest companies occupied for a share nearly % in 2024.
The 鈥淒rug Particle Engineering Service Industry Forecast鈥� looks at past sales and reviews total world Drug Particle Engineering Service sales in 2024, providing a comprehensive analysis by region and market sector of projected Drug Particle Engineering Service sales for 2025 through 2031. With Drug Particle Engineering Service sales broken down by region, market sector and sub-sector, this report provides a detailed analysis in US$ millions of the world Drug Particle Engineering Service industry.
This Insight Report provides a comprehensive analysis of the global Drug Particle Engineering Service landscape and highlights key trends related to product segmentation, company formation, revenue, and market share, latest development, and M&A activity. This report also analyses the strategies of leading global companies with a focus on Drug Particle Engineering Service portfolios and capabilities, market entry strategies, market positions, and geographic footprints, to better understand these firms鈥� unique position in an accelerating global Drug Particle Engineering Service market.
This Insight Report evaluates the key market trends, drivers, and affecting factors shaping the global outlook for Drug Particle Engineering Service and breaks down the forecast by Type, by Application, geography, and market size to highlight emerging pockets of opportunity. With a transparent methodology based on hundreds of bottom-up qualitative and quantitative market inputs, this study forecast offers a highly nuanced view of the current state and future trajectory in the global Drug Particle Engineering Service.
This report presents a comprehensive overview, market shares, and growth opportunities of Drug Particle Engineering Service market by product type, application, key players and key regions and countries.
Segmentation by Type:
Standard Drug Particle Engineering Service
Customized Drug Particle Engineering Service
Segmentation by Application:
Oral Medications
Parenteral Medications
Inhaled Medications
Others
This report also splits the market by region:
Americas
United States
Canada
Mexico
Brazil
APAC
China
Japan
Korea
Southeast Asia
India
Australia
Europe
Germany
France
UK
Italy
Russia
Middle East & Africa
Egypt
South Africa
Israel
Turkey
GCC Countries
The below companies that are profiled have been selected based on inputs gathered from primary experts and analyzing the company's coverage, product portfolio, its market penetration.
Lonza
CritiTech
EUROAPI
Schedio
Solid State Pharma
Hovione
Evonik
Balchem
AP-Process
Micromeritics
Wuxi AppTec
Xedev
Munit
Please Note - This is an on demand report and will be delivered in 2 business days (48 hours) post payment.
1 Scope of the Report
1.1 麻豆原创 Introduction
1.2 Years Considered
1.3 Research Objectives
1.4 麻豆原创 Research Methodology
1.5 Research Process and Data Source
1.6 Economic Indicators
1.7 Currency Considered
1.8 麻豆原创 Estimation Caveats
2 Executive Summary
2.1 World 麻豆原创 Overview
2.1.1 Global Drug Particle Engineering Service 麻豆原创 Size (2020-2031)
2.1.2 Drug Particle Engineering Service 麻豆原创 Size CAGR by Region (2020 VS 2024 VS 2031)
2.1.3 World Current & Future Analysis for Drug Particle Engineering Service by Country/Region (2020, 2024 & 2031)
2.2 Drug Particle Engineering Service Segment by Type
2.2.1 Standard Drug Particle Engineering Service
2.2.2 Customized Drug Particle Engineering Service
2.3 Drug Particle Engineering Service 麻豆原创 Size by Type
2.3.1 Drug Particle Engineering Service 麻豆原创 Size CAGR by Type (2020 VS 2024 VS 2031)
2.3.2 Global Drug Particle Engineering Service 麻豆原创 Size 麻豆原创 Share by Type (2020-2025)
2.4 Drug Particle Engineering Service Segment by Application
2.4.1 Oral Medications
2.4.2 Parenteral Medications
2.4.3 Inhaled Medications
2.4.4 Others
2.5 Drug Particle Engineering Service 麻豆原创 Size by Application
2.5.1 Drug Particle Engineering Service 麻豆原创 Size CAGR by Application (2020 VS 2024 VS 2031)
2.5.2 Global Drug Particle Engineering Service 麻豆原创 Size 麻豆原创 Share by Application (2020-2025)
3 Drug Particle Engineering Service 麻豆原创 Size by Player
3.1 Drug Particle Engineering Service 麻豆原创 Size 麻豆原创 Share by Player
3.1.1 Global Drug Particle Engineering Service Revenue by Player (2020-2025)
3.1.2 Global Drug Particle Engineering Service Revenue 麻豆原创 Share by Player (2020-2025)
3.2 Global Drug Particle Engineering Service Key Players Head office and Products Offered
3.3 麻豆原创 Concentration Rate Analysis
3.3.1 Competition Landscape Analysis
3.3.2 Concentration Ratio (CR3, CR5 and CR10) & (2023-2025)
3.4 New Products and Potential Entrants
3.5 Mergers & Acquisitions, Expansion
4 Drug Particle Engineering Service by Region
4.1 Drug Particle Engineering Service 麻豆原创 Size by Region (2020-2025)
4.2 Global Drug Particle Engineering Service Annual Revenue by Country/Region (2020-2025)
4.3 Americas Drug Particle Engineering Service 麻豆原创 Size Growth (2020-2025)
4.4 APAC Drug Particle Engineering Service 麻豆原创 Size Growth (2020-2025)
4.5 Europe Drug Particle Engineering Service 麻豆原创 Size Growth (2020-2025)
4.6 Middle East & Africa Drug Particle Engineering Service 麻豆原创 Size Growth (2020-2025)
5 Americas
5.1 Americas Drug Particle Engineering Service 麻豆原创 Size by Country (2020-2025)
5.2 Americas Drug Particle Engineering Service 麻豆原创 Size by Type (2020-2025)
5.3 Americas Drug Particle Engineering Service 麻豆原创 Size by Application (2020-2025)
5.4 United States
5.5 Canada
5.6 Mexico
5.7 Brazil
6 APAC
6.1 APAC Drug Particle Engineering Service 麻豆原创 Size by Region (2020-2025)
6.2 APAC Drug Particle Engineering Service 麻豆原创 Size by Type (2020-2025)
6.3 APAC Drug Particle Engineering Service 麻豆原创 Size by Application (2020-2025)
6.4 China
6.5 Japan
6.6 South Korea
6.7 Southeast Asia
6.8 India
6.9 Australia
7 Europe
7.1 Europe Drug Particle Engineering Service 麻豆原创 Size by Country (2020-2025)
7.2 Europe Drug Particle Engineering Service 麻豆原创 Size by Type (2020-2025)
7.3 Europe Drug Particle Engineering Service 麻豆原创 Size by Application (2020-2025)
7.4 Germany
7.5 France
7.6 UK
7.7 Italy
7.8 Russia
8 Middle East & Africa
8.1 Middle East & Africa Drug Particle Engineering Service by Region (2020-2025)
8.2 Middle East & Africa Drug Particle Engineering Service 麻豆原创 Size by Type (2020-2025)
8.3 Middle East & Africa Drug Particle Engineering Service 麻豆原创 Size by Application (2020-2025)
8.4 Egypt
8.5 South Africa
8.6 Israel
8.7 Turkey
8.8 GCC Countries
9 麻豆原创 Drivers, Challenges and Trends
9.1 麻豆原创 Drivers & Growth Opportunities
9.2 麻豆原创 Challenges & Risks
9.3 Industry Trends
10 Global Drug Particle Engineering Service 麻豆原创 Forecast
10.1 Global Drug Particle Engineering Service Forecast by Region (2026-2031)
10.1.1 Global Drug Particle Engineering Service Forecast by Region (2026-2031)
10.1.2 Americas Drug Particle Engineering Service Forecast
10.1.3 APAC Drug Particle Engineering Service Forecast
10.1.4 Europe Drug Particle Engineering Service Forecast
10.1.5 Middle East & Africa Drug Particle Engineering Service Forecast
10.2 Americas Drug Particle Engineering Service Forecast by Country (2026-2031)
10.2.1 United States 麻豆原创 Drug Particle Engineering Service Forecast
10.2.2 Canada 麻豆原创 Drug Particle Engineering Service Forecast
10.2.3 Mexico 麻豆原创 Drug Particle Engineering Service Forecast
10.2.4 Brazil 麻豆原创 Drug Particle Engineering Service Forecast
10.3 APAC Drug Particle Engineering Service Forecast by Region (2026-2031)
10.3.1 China Drug Particle Engineering Service 麻豆原创 Forecast
10.3.2 Japan 麻豆原创 Drug Particle Engineering Service Forecast
10.3.3 Korea 麻豆原创 Drug Particle Engineering Service Forecast
10.3.4 Southeast Asia 麻豆原创 Drug Particle Engineering Service Forecast
10.3.5 India 麻豆原创 Drug Particle Engineering Service Forecast
10.3.6 Australia 麻豆原创 Drug Particle Engineering Service Forecast
10.4 Europe Drug Particle Engineering Service Forecast by Country (2026-2031)
10.4.1 Germany 麻豆原创 Drug Particle Engineering Service Forecast
10.4.2 France 麻豆原创 Drug Particle Engineering Service Forecast
10.4.3 UK 麻豆原创 Drug Particle Engineering Service Forecast
10.4.4 Italy 麻豆原创 Drug Particle Engineering Service Forecast
10.4.5 Russia 麻豆原创 Drug Particle Engineering Service Forecast
10.5 Middle East & Africa Drug Particle Engineering Service Forecast by Region (2026-2031)
10.5.1 Egypt 麻豆原创 Drug Particle Engineering Service Forecast
10.5.2 South Africa 麻豆原创 Drug Particle Engineering Service Forecast
10.5.3 Israel 麻豆原创 Drug Particle Engineering Service Forecast
10.5.4 Turkey 麻豆原创 Drug Particle Engineering Service Forecast
10.6 Global Drug Particle Engineering Service Forecast by Type (2026-2031)
10.7 Global Drug Particle Engineering Service Forecast by Application (2026-2031)
10.7.1 GCC Countries 麻豆原创 Drug Particle Engineering Service Forecast
11 Key Players Analysis
11.1 Lonza
11.1.1 Lonza Company Information
11.1.2 Lonza Drug Particle Engineering Service Product Offered
11.1.3 Lonza Drug Particle Engineering Service Revenue, Gross Margin and 麻豆原创 Share (2020-2025)
11.1.4 Lonza Main Business Overview
11.1.5 Lonza Latest Developments
11.2 CritiTech
11.2.1 CritiTech Company Information
11.2.2 CritiTech Drug Particle Engineering Service Product Offered
11.2.3 CritiTech Drug Particle Engineering Service Revenue, Gross Margin and 麻豆原创 Share (2020-2025)
11.2.4 CritiTech Main Business Overview
11.2.5 CritiTech Latest Developments
11.3 EUROAPI
11.3.1 EUROAPI Company Information
11.3.2 EUROAPI Drug Particle Engineering Service Product Offered
11.3.3 EUROAPI Drug Particle Engineering Service Revenue, Gross Margin and 麻豆原创 Share (2020-2025)
11.3.4 EUROAPI Main Business Overview
11.3.5 EUROAPI Latest Developments
11.4 Schedio
11.4.1 Schedio Company Information
11.4.2 Schedio Drug Particle Engineering Service Product Offered
11.4.3 Schedio Drug Particle Engineering Service Revenue, Gross Margin and 麻豆原创 Share (2020-2025)
11.4.4 Schedio Main Business Overview
11.4.5 Schedio Latest Developments
11.5 Solid State Pharma
11.5.1 Solid State Pharma Company Information
11.5.2 Solid State Pharma Drug Particle Engineering Service Product Offered
11.5.3 Solid State Pharma Drug Particle Engineering Service Revenue, Gross Margin and 麻豆原创 Share (2020-2025)
11.5.4 Solid State Pharma Main Business Overview
11.5.5 Solid State Pharma Latest Developments
11.6 Hovione
11.6.1 Hovione Company Information
11.6.2 Hovione Drug Particle Engineering Service Product Offered
11.6.3 Hovione Drug Particle Engineering Service Revenue, Gross Margin and 麻豆原创 Share (2020-2025)
11.6.4 Hovione Main Business Overview
11.6.5 Hovione Latest Developments
11.7 Evonik
11.7.1 Evonik Company Information
11.7.2 Evonik Drug Particle Engineering Service Product Offered
11.7.3 Evonik Drug Particle Engineering Service Revenue, Gross Margin and 麻豆原创 Share (2020-2025)
11.7.4 Evonik Main Business Overview
11.7.5 Evonik Latest Developments
11.8 Balchem
11.8.1 Balchem Company Information
11.8.2 Balchem Drug Particle Engineering Service Product Offered
11.8.3 Balchem Drug Particle Engineering Service Revenue, Gross Margin and 麻豆原创 Share (2020-2025)
11.8.4 Balchem Main Business Overview
11.8.5 Balchem Latest Developments
11.9 AP-Process
11.9.1 AP-Process Company Information
11.9.2 AP-Process Drug Particle Engineering Service Product Offered
11.9.3 AP-Process Drug Particle Engineering Service Revenue, Gross Margin and 麻豆原创 Share (2020-2025)
11.9.4 AP-Process Main Business Overview
11.9.5 AP-Process Latest Developments
11.10 Micromeritics
11.10.1 Micromeritics Company Information
11.10.2 Micromeritics Drug Particle Engineering Service Product Offered
11.10.3 Micromeritics Drug Particle Engineering Service Revenue, Gross Margin and 麻豆原创 Share (2020-2025)
11.10.4 Micromeritics Main Business Overview
11.10.5 Micromeritics Latest Developments
11.11 Wuxi AppTec
11.11.1 Wuxi AppTec Company Information
11.11.2 Wuxi AppTec Drug Particle Engineering Service Product Offered
11.11.3 Wuxi AppTec Drug Particle Engineering Service Revenue, Gross Margin and 麻豆原创 Share (2020-2025)
11.11.4 Wuxi AppTec Main Business Overview
11.11.5 Wuxi AppTec Latest Developments
11.12 Xedev
11.12.1 Xedev Company Information
11.12.2 Xedev Drug Particle Engineering Service Product Offered
11.12.3 Xedev Drug Particle Engineering Service Revenue, Gross Margin and 麻豆原创 Share (2020-2025)
11.12.4 Xedev Main Business Overview
11.12.5 Xedev Latest Developments
11.13 Munit
11.13.1 Munit Company Information
11.13.2 Munit Drug Particle Engineering Service Product Offered
11.13.3 Munit Drug Particle Engineering Service Revenue, Gross Margin and 麻豆原创 Share (2020-2025)
11.13.4 Munit Main Business Overview
11.13.5 Munit Latest Developments
12 Research Findings and Conclusion
听
听
*If Applicable.
